Ciclosporin has been investigated as a treatment for a number of other autoimmune conditions where it has not been found to have a major role either because of limited efficacy or nephrotoxicity. Ciclosporin is active against uveitis (Nussenblatt et al. 1985) but because of problems with nephrotoxicity (Palestine et al. 1986; Austin et al. 1989) it is usually reserved for cases which are refractory to other therapy or severe bilateral sight-threatening uveitis (Walton et al. 1998).
Type 1 diabetes is an autoimmune disease. Ciclosporin has been found to increase the frequency and duration of early remission of disease but has not been found to alter the long-term outcome or need for insulin therapy (The Canadian-European Randomized Control Trial Group 1988).
Ciclosporin has been used in the treatment of acute severe ulcerative colitis that has failed to respond to high-dose corticosteroid therapy. However, these patients are usually referred for colectomy because remission may only be short term and because of the risk of nephrotoxicity (McCormack et al. 2002). Ciclosporin may have a role as a corticosteroid-sparing agent in patients with chronic ulcerative colitis (Actis et al. 1999).
Was this article helpful?